Silexion Therapeutics completes key study on SIL-204 in pancreatic cancer models, initial results expected soon

Silexion Therapeutics Corp. (NASDAQ: SLXN), a clinical-stage biotechnology company developing RNA interference therapy, has reached a major milestone with the completion of its initial study ... Read More